This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Confluence Pharmaceuticals, LLC
Drug Names(s): Acamprosate Calcium
Description: Confluence Pharmaceuticals is developing a product using Acamprosate Calcium. Acamprosate is thought to stabilize the chemical balance in the brain that would otherwise be disrupted by alcohol withdrawal or benzodiazepine withdrawal.
AOP Orphan and Confluence
In March 2015, Confluence Pharmaceuticals and AOP Orphan signed a definitive agreement to co-develop and market Confluences lead asset, a product for the treatment of Fragile X Syndrome in Europe and the Middle East.
Partners: AOP Orphan Pharmaceuticals AG
Pink Sheet Lipha acamprosate for alcohol dependence
Pink Sheet Merck KgaA Campral
Additional information available to subscribers only: